Clinical value of ACR O-RADS combined with CA125 in the risk stratification of adnexal masses
Open Access
- 30 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1369900
Abstract
Purpose: To develop a combined diagnostic model integrating the subclassification of the 2022 version of the American College of Radiology (ACR) Ovarian-Adnexal Reporting and Data System (O-RADS) with carbohydrate antigen 125 (CA125) and to validate whether the combined model can offer superior diagnostic efficacy than O-RADS alone in assessing adnexal malignancy risk.Methods: A retrospective analysis was performed on 593 patients with adnexal masses (AMs), and the pathological and clinical data were included. According to the large differences in malignancy risk indices for different image features in O-RADS category 4, the lesions were categorized into groups A and B. A new diagnostic criterion was developed. Lesions identified as category 1, 2, 3, or 4A with a CA125 level below 35 U/ml were classified as benign. Lesions identified as category 4A with a CA125 level more than or equal to 35 U/ml and lesions with a category of 4B and 5 were classified as malignant. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the curve (AUC) of O-RADS (v2022), CA125, and the combined model in the diagnosis of AMs were calculated and compared.Results: The sensitivity, specificity, PPV, NPV, accuracy, and AUCs of the combined model were 92.4%, 96.5%, 80.2%, 98.8%, 94.1%, and 0.945, respectively. The specificity, PPV, accuracy, and AUC of the combined model were significantly higher than those of O-RADS alone (all P < 0.01). In addition, both models had acceptable sensitivity and NPV, but there were no significant differences among them (P > 0.05).Conclusion: The combined model integrating O-RADS subclassification with CA125 could improve the specificity and PPV in diagnosing malignant AMs. It could be a valuable tool in the clinical application of risk stratification of AMs.Keywords
This publication has 47 references indexed in Scilit:
- External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk GroupsJAMA Oncology, 2023
- Diagnostic Performance of the Ovarian-Adnexal Reporting and Data System (O-RADS) Ultrasound Risk Score in Women in the United StatesJAMA Network Open, 2022
- O-RADS MRI score: analysis of misclassified cases in a prospective multicentric European cohortEuropean Radiology, 2021
- Comparison of O-RADS, GI-RADS, and IOTA simple rules regarding malignancy rate, validity, and reliability for diagnosis of adnexal massesEuropean Radiology, 2020
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non‐invasive malignant serous ovarian tumorsUltrasound in Obstetrics & Gynecology, 2017
- The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive reviewClinical & Experimental Metastasis, 2017
- External validation of IOTA simple descriptors and simple rules for classifying adnexal massesUltrasound in Obstetrics & Gynecology, 2016
- Imaging in gynecological disease (1): ultrasound features of metastases in the ovaries differ depending on the origin of the primary tumorUltrasound in Obstetrics & Gynecology, 2007
- Clinical Value of CA125, CA19-9, CEA, CA72-4, and TPA in Borderline Ovarian TumorGynecologic Oncology, 1996